<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/42CE62AA-63C7-447E-8692-AE40469EF4A2"><gtr:id>42CE62AA-63C7-447E-8692-AE40469EF4A2</gtr:id><gtr:firstName>Anatoli</gtr:firstName><gtr:surname>Kamali</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_1204%2F6"><gtr:id>D4F2B0D3-DC3A-476C-9549-0B31703B7E6D</gtr:id><gtr:title>HIV EPIDEMIOLOGY AND PREVENTION / A RANDOMISED, PLACEBO-CONTROLLED SAFETY AND EFFICACY TRIAL OF A DAPIVIRINE VAGINAL RING IN HEALTHY HIV-NEGATIVE WOMEN</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_1204/6</gtr:grantReference><gtr:abstractText>HIV/AIDS is the leading cause of death globally in women aged 15 to 44, and exerts an especially high toll in sub-Saharan Africa, where 60% of people living with HIV are women and girls. Developing new HIV prevention options that women can use remains a public health priority. The current generation of vaginal microbicide candidates, containing highly-specific antiretroviral (ARV) drugs, are currently undergoing extensive safety and efficacy trials. ARV-based microbicides specifically target HIV and can be designed in various forms (e.g. vaginal gels, rings, films, tablets) for more flexible dosing, including products for use around the time of sex, or daily or monthly products that could be used independent of sexual activity. Other recently completed and ongoing clinical trials are exploring whether oral daily ARVs taken as pre-exposure prophylaxis (PrEP) are safe and effective for HIV prevention.
Recent research confirms the potential of ARV-based HIV prevention. It thus appears that ARV approaches to prevention have the potential to transform the response to the HIV/AIDS pandemic. In order for a microbicide to be most effective, it is essential that it is used correctly and consistently, and is acceptable to women and their male partners. In addition, a product used independently of sex could be more convenient for women and provide long-term protection during anticipated and unanticipated sexual intercourse.</gtr:abstractText><gtr:technicalSummary>IPM 027 is a multi-centre, randomised, double-blind, placebo-controlled trial to assess the safety and efficacy of dapivirine in a silicone elastomer vaginal matrix ring, inserted once every 4 weeks in healthy, sexually active HIV-negative women, when compared to a placebo vaginal ring. The trial will be conducted at approximately 7 clinical research centres in sub-Saharan Africa and Uganda. Approximately 1,650 participants will be randomised to receive either the 25 mg dapivirine vaginal ring or a placebo vaginal ring.
Each participant will engage in the screening period of up to 4 weeks (28 days) prior to enrolment, and will use the IP for an estimated period of 24 months (104 weeks). Each participant will have an additional 6 weeks of follow-up after ring discontinuation to assess for safety and identify HIV seroconversions after product discontinuation.
The primary endpoints are:
? The incidence rate of HIV-1 seroconversion;
? All adverse events (AEs) (full descriptive evaluation).
The secondary endpoints are:
? The incidence rate of HIV-2 seroconversion;
? The incidence of curable STIs (i.e. N.gonorrhoea, C.trachomatis and T.vaginalis), and changes in vaginal flora in each trial arm over the IP use period;
? The incidence of pregnancy in each trial arm over the IP use period;
? The proportion of women who report adherence to the use of the vaginal ring inserted once every 4 weeks over the trial period;
? The proportion of women who report the use of the vaginal ring as acceptable;
? The proportion of participants with HIV-1 drug resistance mutations among participants who acquire HIV-1.</gtr:technicalSummary><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>804353</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_1204/6</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>